Findings, methods and field notes from the team building diagnostic infrastructure.
Featured
Proteomics alone delivers almost all of Aurora's prognostic power, simplifying the path to a deployable CV-death test. UK Biobank (N ≈ 500,000).
Predicting cardiovascular death among patients who already have heart failure, using multimodal machine learning on UK Biobank (N ≈ 500,000).
Using an Aurora prognostic signature to concentrate CV-death events and shrink outcomes trials.
Aurora’s discovered CV-death proteins map to established and emerging druggable biology.
Why a proteomic panel predicts cardiovascular death in heart failure far better than NT-proBNP alone.
Five signals from this year's posters, and what they mean for anyone trying to take a biomarker from discovery to the clinic.
Moving beyond binary inclusion and exclusion criteria with ML-driven continuous risk scoring at population scale.
103 articles · page 1 of 9
